Dovitinib (TKI258)
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for Dovitinib (TKI258), covering 2015-03-31 to 2015-03-31. Get the full timeline:
Most recent: Clinical Trial Update: A Phase II Study to Evaluate the Efficacy of TKI258 for the Treatment of Patients With FGFR2 Mutated or Wild-type Advanced and/or Metastatic Endometrial Cancer [Phase 2]